#United States #Pleasanton #10x Genomics #Spatial Biology #TXG

10x Genomics Reports Initial Q4 and Full Year Financial Outcomes for 2025

10x Genomics, Inc., known for its advancements in single-cell and spatial biology, recently shared preliminary and unaudited financial results for the fourth quarter and full year ending December 31, 2025. This report highlights both growth and challenges faced throughout the year.

Q4 2025 Highlights

For the last quarter of 2025, 10x Genomics recorded total revenue of approximately $166.0 million, marking an 11% sequential growth and a 1% increase compared to the same quarter in the previous year. Here’s a detailed breakdown of the key revenue streams:

• - Instruments Revenue: Approximately $15.5 million, which corresponds to a significant 29% sequential growth but a 36% decrease year-over-year. This revenue includes $6.1 million from Single Cell instruments (24% growth sequentially) and $9.4 million from Spatial instruments (32% growth sequentially).

• - Consumables Revenue: Approximately $141.7 million, showing a 11% sequential increase and a 6% rise year-over-year. Notably, Single Cell consumables contributed about $100.8 million (a 9% sequential growth), while Spatial consumables stood at around $41.0 million with a 16% growth.

• - Services and Licenses Revenue: This segment totaled approximately $8.8 million, a slight 3% decrease sequentially but a 23% increase year-over-year.

Full Year 2025 Overview

Over the entire year, 10x Genomics reported total revenue of approximately $642.8 million. It is crucial to note that when excluding $44.1 million related to patent litigation settlements from earlier quarters, the revenue for the full year amounts to approximately $598.7 million, which represents a 2% decrease compared to 2024. Key points for the year include:

• - Instruments Revenue: Totaling about $56.8 million, this illustrated a 39% decline from the previous year. Within this, Single Cell instruments generated approximately $22.7 million, down 36% year-over-year, while Spatial instruments garnered around $34.1 million, down 41% year-over-year.

• - Consumables Revenue: Approximately $507.2 million, reflecting a 3% growth from the prior year. Of this, Single Cell consumables made up about $363.2 million, down 2% year-over-year, with Spatial consumables achieving significant progress at $144.0 million, which represents 19% growth.

• - Services and License Revenue: Reaching approximately $34.8 million (excluding the earlier settlements), this figure indicates a substantial 41% growth from the previous year.

• - The company also highlighted that it has successfully sold more than 6,400 Chromium instruments and over 1,500 Spatial instruments by the close of 2025. Furthermore, there was a notable increase of over 20% in Single Cell consumable reactions sold compared to the previous year.

As of December 31, 2025, 10x Genomics reported a strong cash position, with approximately $520 million in cash, cash equivalents, and marketable securities.

Forward-Looking Statements and Conclusion

Serge Saxonov, the Co-founder and CEO of 10x Genomics, expressed pride in the accomplishments of the team throughout 2025, particularly emphasizing how they navigated challenges in the macro environment, strengthened customer partnerships, and progressed with their product roadmap. He conveyed confidence in the potential impact of their innovations moving forward.

10x Genomics is set to further discuss these developments at the 44th Annual J.P. Morgan Healthcare Conference, with a live webcast commencing at 8:15 a.m. Pacific Time on January 12, 2026. This presentation will also be available for replay on the company’s investor relations website for at least 30 days following the event.

While these preliminary results are subject to change, they reflect 10x Genomics’ resilience and innovative contributions to life sciences, positioning the company favorably for future opportunities in the field of spatial biology.